During the past decade, Sudarshan K Sharma MD Limited-Gynecologic Oncology conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 52 clinical trials were completed, i.e. on average, 260% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 25 clinical trials were completed. i.e. 357.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 35 trials, followed by "Gynecologic Oncology Group" with 17 trials sponsored, "GOG Foundation" with 10 trials sponsored, "NRG Oncology" with 2 trials sponsored and "Aravive, Inc." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" #1 collaborator was "NRG Oncology" with 34 trials as a collaborator, "National Cancer Institute (NCI)" with 29 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 4 trials as a collaborator, "Gynecologic Oncology Group" with 3 trials as a collaborator and "GOG Foundation" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" are "Recurrent Ovarian Carcinoma" (19 trials), "Recurrent Fallopian Tube Carcinoma" (16 trials), "Recurrent Primary Peritoneal Carcinoma" (15 trials), "Ovarian Seromucinous Carcinoma" (11 trials) and "Endometrial Clear Cell Adenocarcinoma" (9 trials). Many other conditions were trialed in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" in a lesser frequency.

Most popular intervention types in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" are "Drug" (58 trials), "Other" (50 trials), "Biological" (24 trials), "Procedure" (12 trials) and "Radiation" (6 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (33 trials), "Paclitaxel" (27 trials), "Quality-of-Life Assessment" (20 trials), "Carboplatin" (17 trials) and "Bevacizumab" (12 trials). Other intervention names were less common.

The vast majority of trials in "Sudarshan K Sharma MD Limited-Gynecologic Oncology" are 70 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Sudarshan K Sharma MD Limited-Gynecologic Oncology". undefined are not yet recruiting, 4 are recruiting, 28 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Sudarshan K Sharma MD Limited-Gynecologic Oncology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Sudarshan K Sharma MD Limited-Gynecologic Oncology, 0 "Phase 1" clinical trials were conducted, 41 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".